anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients randomized to the experimental group (CT-FFR guided group) will undergo coronary artery three-dimensional reconstruction and CT-FFR calculation using the coronary CT angiography (CCTA) images and RuiXin-FFR software. The researchers will interpret and analyze the clinical outcomes based on CT-FFR results. If CT-FFR is \>0.8, the patient will be treated with medical therapy alone. If CT-FFR is ≤0.8, further examination with coronary angiography will be performed. During the angiography examination, the operator will determine the treatment strategy (PCI, CABG, or medical therapy alone) based on the anatomical features of the lesion and the CT-FFR results.
Monotherapy — Olanzapine Tablets, USP are indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. Efficacy was established in three clinical trials in adult patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one monotherapy maintenance trial. [see Clinical Studies (14.2)]. 

     When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and hyperlipidemia. Clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents  [see Warnings and Precautions ( 5.5 ,  5.6 )] . 

Information describing the use of olanzapine tablets and olanzapine orally disintegrating tablets in pediatric patients with bipolar I disorder is approved for Eli Lilly and Company’s olanzapine drug product labeling. However, due to Eli Lilly and Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

Adjunctive Therapy to Lithium or Valproate — Olanzapine Tablets, USP are indicated for the treatment of manic or mixed episodes associated with bipolar I disorder as an adjunct to lithium or valproate. Efficacy was established in two 6-week clinical trials in adults. The effectiveness of adjunctive therapy for longer-term use has not been systematically evaluated in controlled trials [see Clinical Studies (14.2)].
A preparation method of an edible traditional Chinese medicine hair dye with homology of medicine and food relates to a preparation method of a hair dye, in particular to a preparation method of a traditional Chinese medicine hair dye. The invention aims to solve the problems that the existing hair dye is added with toxic and harmful substances, is easy to cause cancers, is easy to be allergic, is easy to damage hair quality and the like. The preparation method comprises the following steps: 1. preparing gardenia water extract; 2. preparing a fermentation substrate; 3. fermenting to obtain fermented soya beans; 4. preparing a culture solution; 5. preparing rice bran fermentation liquor; 6. performing synergistic fermentation to obtain fresh fermented soya beans; 7. preparing an aqueous solution of the gardenia and the fermented soybean; 8. mixing, extracting and drying to obtain the edible medicinal and edible traditional Chinese medicine hair dye. The advantages are that: the content of polyglutamic acid is increased, and the tinting strength is strong; high yield of gardenia blue pigment. The color fastness is not easy to fade. The invention is mainly used for preparing the hair dye.
The present invention is directed to microcapsules for reliably modified release and adapted to industrial reproduction of an active principle hardly water-soluble, other than anti-hyperglycemia agents. Each of said microcapsules comprises a core of hardly soluble active principle and a coating film applied on the core. Their mean diameter is less than 1000 microns. The coating film contains a film-forming polymer (PI) insoluble in gastrointestinal tract fluids, a water-soluble polymer (P2), a plasticizer (PL), and optionally a lubricating surfactant (TA). Said coating film represents at least 4% p/p of dry matter of their total weight, and its components P1, P2, PL satisfy the following characteristics: dry weight mass fraction of PI relative to the total coating weight ranging between 40 and 90%; dry matter weight fraction of PL/P1+P2 ranging between 15 and 60%; dry matter weight fraction of PL/P1+P2 ranging between 1 and 30%. The present invention is also directed to the uses of said microcapsules in galenic formulation.
BACKGROUND: The healthcare system in India is tiered and has primary, secondary and tertiary levels of facilities depending on the complexity and severity of health challenges at these facilities. Evidence suggests that emergency services in the country is fragmented. This study aims to identify the barriers and facilitators of emergency care delivery for patients with time-sensitive conditions, and develop and implement a contextually relevant model, and measure its impact using implementation research outcomes.
METHODS: We will study 85 healthcare facilities across five zones of the country and focus on emergency care delivery for 11 time-sensitive conditions. This implementation research will include seven phases: the preparatory phase, formative assessment, co-design of Model "Zero", co-implementation, model optimization, end-line evaluation and consolidation phase. The "preparatory phase" will involve stakeholder meetings, approval from health authorities and the establishment of a research ecosystem. The "formative assessment" will include quantitative and qualitative evaluations of the existing healthcare facilities and personnel to identify gaps, barriers and facilitators of emergency care services for time-sensitive conditions. On the basis of the results of the formative assessment, context-specific implementation strategies will be developed through meetings with stakeholders, providers and experts. The "co-design of Model 'Zero'" phase will help develop the initial Model "Zero", which will be pilot tested on a small scale (co-implementation). In the "model optimization" phase, iterative feedback loops of meetings and testing various strategies will help develop and implement the final context-specific model. End-line evaluation will assess implementation research outcomes such as acceptability, adoption, fidelity and penetration. The consolidation phase will include planning for the sustenance of the interventions.
DISCUSSION: In a country such as India, where resources are scarce, this study will identify the barriers and facilitators to delivering emergency care services for time-sensitive conditions across five varied zones of the country. Stakeholder and provider participation in developing consensus-based implementation strategies, along with iterative cycles of meetings and testing, will help adapt these strategies to local needs. This approach will ensure that the developed models are practical, feasible and tailored to the specific challenges and requirements of each region.
Doxorubicin-induced cardiotoxicity (DIC) poses a significant challenge, impeding its widespread application. Emerging evidence suggests the involvement of ferroptosis in the DIC. While the downregulation of SLC7A11 expression has been linked to the promotion of ferroptosis, the precise regulatory mechanism remains unclear. Recent studies, including our own, have highlighted abnormal levels of autophagy adapter protein P62 and autophagy in DIC development. Thus, our study aimed to further investigate the role of autophagy and ferroptosis in DIC, elucidating underlying molecular mechanisms across molecular, cellular, and whole-organ levels utilizing gene knockdown, immunoprecipitation, and mass spectrometry techniques. The results of our findings unveiled cardiomyocyte damage, heightened autophagy levels, and ferroptosis in DOX-treated mouse hearts. Notably, inhibition of autophagy levels attenuated DOX-induced ferroptosis. Mechanistically, we discovered that the autophagy adaptor protein P62 mediates the entry of SLC7A11 into the autophagic pathway for degradation. Furthermore, the addition of autophagy inhibitors (CQ or BAF) could elevate SLC7A11 and GPX4 protein expression, reduce the accumulation of Fe2+ and ROS in cardiomyocytes, and thus mitigate DOX-induced ferroptosis. In summary, our findings underscore the pivotal role of the P62-autophagy pathway in SLC7A11 degradation, modulating ferroptosis to exacerbate DIC. This finding offers significant insights into the underlying molecular mechanisms of DOX-induced ferroptosis and identifies new targets for reversing DIC.
The invention belongs to a traditional Chinese medicine, and particularly relates to a traditional Chinese medicine for treating infant parotitis. The invention is characterized in that the traditional Chinese medicine is composed of the following components in parts by weight: 40-50g of fresh taraxacum and 20-40g of white sugar. The traditional Chinese medicine is decocted in clear water with soft fire for 15 minutes or so. The decoction is taken 1 dose a day, and every dose is taken by two times. The patient can recover within 5-10 days. The invention is on the basis of the traditional Chinese medicine authentication theory, has the advantages of simple formula, accessible materials, low cost, high curative effect and no toxic or side effect, and effectively treats infant parotitis.
Psychosis can be considered a dimension that in its most severe extreme can be expressed with alterations in sensory perception, mainly hallucinations. Their presence is a fact that is frequently observed in severe psychiatric pathologies such as schizophrenia (EZQ) and bipolar disorder (BD) where they can be markers of severity. However, sensory-perceptual disturbances are not pathognomonic of these disorders, nor do they signal any of these illnesses as an isolated event. Such symptomatology can be described in a variety of situations both within and outside psychopathology. In this sense, proposing a direct line between hallucinations and diseases such as CZS or TB disregards their occurrence in other pathologies, as is the case of Borderline Personality Disorder (BPD). It is feasible that we may find the expression of pseudo hallucinations or hallucinations in patients with this disorder and their presence may have etiological, clinical and therapeutic connotations that should be reviewed and taken into account in our clinical practice.
This is a double-blind, placebo-controlled, randomized withdrawal study in adult patients (ages ≥18 years) with IH. The study will consist of a Screening Period (up to 28 days), an 8-week Open-Label Phase, and a 4-week Double-Blind Randomized Withdrawal Phase.

The Open-Label Phase of the study will be 8 weeks, which includes a 6-week Dose Optimization Period and a 2-week Stable Dose Period. In the Dose Optimization Period, all patients will be titrated to their optimal dose of open-label pitolisant (17.8 mg or 35.6 mg) based on Investigator assessment of tolerability and efficacy. The 3-week titration period will be followed by 3 weeks of flexible dosing (weeks 4-6) during which patients will continue to receive their optimal dose of 17.8 mg or 35.6 mg open-label pitolisant. Patients taking a strong CYP2D6 inhibitor will be allowed in the study; however, for these patients, the maximum permitted daily dose of pitolisant will be 17.8 mg. Following completion of the 6-week Dose Optimization Period, patients will enter the 2-week Stable Dose Period. During this period, patients will remain at their optimal dose (the same dose they were taking at the end of the Dose Optimization Period \[17.8 mg or 35.6 mg\]) of open-label pitolisant for 2 weeks; dose adjustments are not allowed during the Stable Dose Period. At the end of the Stable Dose Period, patients will be defined as responders or non-responders. Responders will be randomized in a 1:1 ratio to receive blinded study drug (pitolisant or matching placebo) in the Double-Blind Randomized Withdrawal Phase of the study. Non-responders will not be randomized to treatment in the Double-Blind Randomized Withdrawal Phase and will complete two safety follow-up telephone contacts (TCs) at 15 (±3) days and 30 (+3) days after their final dose of open-label pitolisant.

During the Double-Blind Randomized Withdrawal Phase, patients (approximately 64 patients per treatment group) will receive blinded study drug either at the same dose they were taking in the Stable Dose Period (17.8 mg or 35.6 mg pitolisant) or matching placebo. The duration of the Double-Blind Randomized Withdrawal Phase will be 4 weeks (weeks 9-12); dose adjustments are not permitted during this phase of the study. After completion of the Double-Blind Randomized Withdrawal Phase (End-of Treatment \[EOT\] Visit is on Day 84, the last day of blinded treatment), patients will complete two safety follow-up TCs with the site at 15 (±3) days and 30 (+3) days after their final dose of blinded study drug, which will include assessment for AEs and concomitant medication use; alternatively, patients will have the opportunity to enroll in a long-term, open-label safety study under a separate protocol. Patients who opt to enroll into the long-term, open-label study will not complete the 15 day and 30 day follow-up TCs.
The invention especially relates to identified alkaloid compounds with novel skeletons extracted and separated from purslane and an extraction and separation method thereof, belonging to the field of extraction and separation of traditional Chinese medicines. The alkaloid compounds with novel skeletons have molecular formulas of C18H26N2O, C18H24N2O2 and C18H28N2O2, respectively, and are named as oleracimine, oleracimine A and oleracone A, respectively. The invention also provides an extraction and separation method for the novel components. The extraction and separation method successively carries out extraction through water decoction, ethyl acetate extraction and column chromatography on silica gel, an ODS medium-pressure column and Sephadex LH-20 so as to successfully extract and separate the novel alkaloid compounds with unique skeletons. The novel alkaloid compounds have anti-inflammatory, pain-easing and antineoplastic effect. The compounds and salts or derivatives thereof can be used as lead compounds for synthesis of other compounds and as raw materials for development of novel drugs and research on pharmacological activity, and are applicable to preparation of anti-inflammatory, pain-easing and antineoplastic drugs or health products.
Participants receive olaparib orally twice daily for 90 days in the absence of unacceptable toxicity. Beginning 1 day after last olaparib dose, participants undergo radical prostatectomy.
PURPOSE: To remarkably reduce the cost of evaluation and maintenance of microbiological record by connecting a computer with the computer in a laboratory and storing examination data in nodal tree structure and classifying and indicating them in a complex indication matrix. CONSTITUTION: When a computer receives examination reports from the computer in a laboratory, it retrieves the database with the patient ID and identifies the related specimen after confirming its effectiveness. Next, it determines whether it has or not the specimen node, and makes and stores it when not found. When it has the specimen node, the computer compares it with newly received examination data and renews the specimen data stored in the specimen node when there were discrepancies. Next, the computer checks out the biological information and checks out the sensitive information where there is no biological information. It further makes the biological node and relates it with the specimen node where there is sensitive information and no biological information.  When there is biological information, the computer compares it with every biological data and renews it to a new biological information when there is discrepancy. All the results are stored in the nodal tree structure and classified and indicated in the complex indication matrix.
The present invention relates to naloxone eye drop which is used for assisting in judging the addiction and the dependency degree of drug addicts taking opium drugs, and belongs to the technical field of addiction medicine and neurobiology. The naloxone eye drop of the present invention is prepared by a general preparation method, and raw materials comprise solution, preservative agent and naloxone, wherein the naloxone has the content of 0.1 to 5 mg/ml. The pH value of the naloxone eye drop is 6 to 8, and the osmotic pressure is equal to the osmotic pressure of human tears, or is equal to the osmotic pressure of sodium chloride solution of 0.91%, and is 740 kpa. The naloxone eye drop of the present invention has the advantages of low cost, high safety, high reliability, etc. The naloxone eye drop of the present invention is used for thousands of testers, and the accuracy rate of the test result achieves more than 99%. The naloxone eye drop of the present invention can be used as agents for judging the addiction and the dependency degree of drug addicts taking opium drugs.
Group 1 (low molecular weight heparin: bemiparin), which is the study group: after passing the bleeding episode, will receive low molecular weight heparin (bemiparin) in anticoagulant dose. Check should be made by measurement of anti-factor Xa.
The present invention relates to a composition for treating pregnancy-associated diseases and, more particularly, to a pharmaceutical composition including, as an active ingredient, extracellular vesicles derived from the bacteria of  Bacillus  sp. for treating or preventing breast cancer or premature birth, and a method for diagnosing premature birth. The pharmaceutical composition including, as an active ingredient, extracellular vesicles derived from the bacteria of  Bacillus  sp. of the present invention can induce pregnancy or prevent premature birth in pregnant women, and can also be used in the treatment or prevention of pregnancy-associated diseases such as breast cancer. Also, the present invention can be usefully applied to diagnosing the risk of premature birth by measuring the amount of extracellular vesicles derived from the bacteria of  Bacillus  sp. in pregnant women.
ABSTRACT OF THE DISCLOSURE        Viable mammalian cells are encapsulated in a polymeric membrane to form microencapsulated beads ready for introduction into a host body.  The polymeric membrane allows passage therethrough of cell substrates and secretions, but prevents passage of larger molecules such as proteinaceous antibodies.          In this way viable cells secreting essential products such as pancreatic islet cells secreting insulin can be transplanted into a host, and be protected against the immune reactions of the antibodies of the host which would otherwise reject the foreign cells.  The cells are encapsulated from suspension in a non-solvent such as PPG, by addition thereto of a solution of a polymer (e.g. an acrylic/methacrylic acid esters copolymer) in dimethylsulfoxide.  The polymer precipitates onto the cells to encapsulate them, and the supernatants are removed.
This group will receive vasopressin as the first-line vasopressor. DEX will be started after hemodynamic stabilization if the heart rate is \>90 beats per minute (bpm). NE infusion will be the second-line vasoactive drug.
Background Single or multiple point mutations in the tyrosine kinase domain (TKD) of the BCR-ABL1 fusion gene in chronic myeloid leukemia (CML) and Ph-chromosome positive acute lymphoblastic leukemia represent the most important known mechanism of resistance to tyrosine kinase inhibitors (TKIs). It is conceivable that pre-existing point mutations in CML stem cells attributable to the genomic instability conferred by the BCR-ABL1 fusion protein give rise to the outgrowth of resistant subclones and onset of treatment-insensitive disease under the selection pressure of TKI therapy. Early detection of such subclones may therefore be of prognostic and therapeutic relevance. The recently published immunophenotype of CML stem cells (Hermann et al. Blood 2014), and our recent report on an NGS (next-generation sequencing)-based method facilitating sensitive detection and quantitative monitoring of BCR-ABL1 subclones carrying single or compound mutations (Kastner et al. European Journal of Cancer 2014) facilitate the screening for clinically relevant mutant subclones in stem cells or early progenitor cells.

Hypothesis Detection of mutant subclones within the stem cell or early progenitor compartments at diagnosis or early into therapy of Ph-positive leukemias, and monitoring of their proliferation kinetics, permit early prediction of resistant disease under the ongoing TKI treatment.

Experimental approach Bone marrow (BM) and peripheral blood (PB) samples will be collected upon informed consent from patients with Ph-positive leukemia at diagnosis (BM+PB), and subsequently at 3-month intervals (PB;BM upon availability) during the first year of therapy based on or including TKIs. Isolation of CD (cluster of differentiation) 34+ cells carrying additional phenotypic markers characterizing stem cells or early progenitor cells (CD38-/CD25+/CD26+ in CML, CD19 in Ph-ALL) will be performed by flow sorting. The entire BCR-ABL1 tyrosine kinase domain (TKD) will be amplified from cDNA (complementary DNA) or specific exons of interest from DNA by established protocols, and bidirectional sequencing will be performed by ultra-deep sequencing using NGS. Mutant subclones identified at diagnosis or after debulking of most of the treatment-sensitive leukemic burden early into treatment (3 month time point), will be monitored by NGS until month 12 of therapy. BCR-ABL1 transcripts will be monitored according to the International Scale (IS) in parallel. DNA isolated from fingernail clippings will be used as germline control for the ABL1 TKD. The testing will be performed in a blinded fashion to prevent treatment adjustments according to experimental data.
PURPOSE: This scoping review explores various parameters of the mandible in progressive facial asymmetry (FA) in hemifacial microsomia (HFM) patients, highlighting its relationship with sex, population, and age group.
METHODS: The review was based on a comprehensive search of PubMed, EBSCOhost, and Web of Science. Eligible studies that met the inclusion criteria form part of the selection study. The included studies were appraised using screening and quantitative criteria of mixed-method appraisal tools. The authors utilised a pre-set data extraction form to obtain information from the included studies.
RESULTS: Eleven studies met the inclusion criteria. The mandible parameters used were angular measurements, chin point, ramal height, body length, and total length. There was no relationship between FA and sex in HFM patients in the included studies. Most of the studies were comprised of European participants (55%), followed by Americans (36%) and Chinese (9%). The age groups included in the selected studies were categorised as dentition age (18%), early-to-middle childhood (18%), and varied ages (64%). The data presented in this review only pertains to the anomalous characteristics recorded on the affected side in HFM patients. No concomitant control data was recorded in this review.
CONCLUSION: An assessment of the included studies revealed that FA does not increase with age in HFM. Hence, FA is non-progressive in HFM patients. This information is relevant to diagnosing and managing HFM patients. More reports are needed on the progression of FA in HFM patients.
Colitis ulcerosa is treated according to the invention by administering to the patient suffering from such condition an effective dose of penicillamine. The preferred penicillamine because of its low toxicity is D-penicillamine. All types of administration are suitable, including oral administration and administration by injection. The actual dosage depends upon the extent of the condition. Orally the dose may be as little as 0.6 g per day and as high as 2.4 g per day, and even higher for short periods. By injection the dose may be as little as 0.5 g and as high as 1.5 g per day.